

## Supporting information

# Regenerative glycosylation under nucleophilic catalysis


















Swati S. Nigudkar, Keith J. Stine, and Alexei V. Demchenko\*

*Department of Chemistry and Biochemistry, University of Missouri - St. Louis  
One University Boulevard, St. Louis, Missouri 63121, USA  
Fax: (+) 1-314-516-5342; E-mail: [demchenkoa@umsl.edu](mailto:demchenkoa@umsl.edu)*

## Contents

<b>Table 1S.</b> Synthesis of 3,3-difluoro-3 <i>H</i> -indol-2-yl (OFox) imidates	S2
<b>Table 2S.</b> The effect of solvents on the stereoselectivity of glycosidation of per-benzylated OFox donor <b>3</b>	S3
<b>Table 3S.</b> Temperature dependence on the stereoselectivity of glycosidation of per-benzylated OFox donor <b>3</b>	S3
<b>Table 4S.</b> The effect of dilution on the stereoselectivity of glycosidation of per-benzylated OFox donor <b>3</b> with acceptor <b>4</b> in the presence of TMSOTf	S3
<b>Table 5S.</b> The effect of anomeric configuration on the stereoselectivity of glycosidation of OFox donors <b>3</b> and <b>12</b>	S4
<b>Table 6S.</b> The effect of promoter on the stereoselectivity of glycosidation of per-benzylated OFox donor <b>3</b>	S4
<b>Table 7S.</b> Comparative hydrolytic stability study of OFox, trichloro- and trifluoroacetimidates under various reaction conditions	S5
<b>Table 8S.</b> TMSOTf-promoted glycosidation of OFox donor <b>3</b> with different acceptors in CH <sub>2</sub> Cl <sub>2</sub> or EtCN at -78 °C	S6
<b>Table 9S.</b> Glycosylation with per-acylated glucosyl, galactosyl, and mannosyl OFox donors in CH <sub>2</sub> Cl <sub>2</sub> with TMSOTf as a promoter at rt	S7
<b>Table 10S.</b> Regenerative glycosylation, a complete experimental dataset	S8
<b>Scheme 1S.</b> “Regenerative glycosylation” experiment performed in the NMR tube with bromide donor <b>7</b> , HOFox (0.25 equiv.), Ag <sub>2</sub> O (3.0 equiv.) in CDCl <sub>3</sub> at 0 °C in the absence of a glycosyl acceptor	S9
<b>General experimental remarks</b>	S10
<b>Synthesis of 3,3-difluoroxindole (HOFox)</b>	S10
<b>Preparation of OFox imidates</b>	S10
<b>Preparation and characterization of other glycosyl donors and intermediates</b>	S14
<b>General glycosylation procedures for the synthesis of glycosides and disaccharides</b>	S17
<b>A typical procedure for regenerative glycosylation</b>	S23
<b>NMR spectra</b>	S25
<b>References</b>	S73

**Table 1S.** Synthesis of 3,3-difluoro-3*H*-indol-2-yl (OFox) imidates

Entry	Starting material	Conditions, <sup>a</sup> temp, time	Product	Yield, / ratio
1		<b>A</b> , rt, 8 h		62% 10/1
2		<b>A</b> , rt, 12 h		61% only
3		<b>B</b> , 0 °C, 40 min		80% only
4	<b>11</b>	<b>B</b> , rt, 5 h		81% only
5		<b>C</b> , rt, 6 h		80% only
6		<b>B</b> , rt, 10 h		75% only
7		<b>D</b> , 0 °C to rt, 6 h		75% only
8		<b>D</b> , rt, 2.5 h		84% only
9		<b>B</b> , 0 °C to rt, 3 h		70% only

<sup>a</sup> —

Conditions:


**A:** i) SOCl<sub>2</sub>, DMF, CH<sub>2</sub>Cl<sub>2</sub>, ii) 3,3-difluoroxindole, Ag<sub>2</sub>O, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>;

**B:** 3,3-difluoroxindole, Ag<sub>2</sub>O, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>;

**C:** 3,3-difluoroxindole, Ag<sub>2</sub>O, DIPEA, toluene;


**D:** i) 33% HBr/AcOH, CH<sub>2</sub>Cl<sub>2</sub>, ii) 3,3-difluoroxindole, Ag<sub>2</sub>O, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>

**Table 2S.** The effect of solvents on the stereoselectivity of glycosidation of per-benzylated OFox donor **3**.



Entry	Solvent	Temp	Yield of <b>5</b> , %	/ ratio
1	CH <sub>2</sub> Cl <sub>2</sub>	-78 °C	94	1/24
2	Et <sub>2</sub> O	-78 °C	84	1/5.0
3	Et <sub>2</sub> O	50 °C	81	1.6/1
4	THF	50 °C	79	1.4/1
5	CH <sub>3</sub> CN	-40 °C	87	1/14
6	EtCN	-78 °C	99	only
7	CH <sub>2</sub> Cl <sub>2</sub> /CH <sub>3</sub> CN (1/2, v/v)	-40 °C	96	1/6.0
8	CH <sub>2</sub> Cl <sub>2</sub> /CH <sub>3</sub> CN/EtCN (1/2/1, v/v/v)	-78 °C	99	only

**Table 3S.** Temperature dependence on the stereoselectivity of glycosidation of per-benzylated OFox donor **3**.




Entry	Temp	Yield of <b>5</b> , %	/ ratio
1	-78 °C	94	1/24
3	-40 °C	97	1/8.0
4	rt	93	1/1.2
5	50 °C	93	1/1.0

**Table 4S.** The effect of dilution on the stereoselectivity of glycosidation of per-benzylated OFox donor **3** with acceptor **4** in the presence of TMSOTf.


Entry	Solvent	Temp, time	Yield of <b>5</b> , %	/ ratio
1	CH <sub>2</sub> Cl <sub>2</sub> (86 mM)	-78 °C, 10 min	94	1/24
2	EtCN (86 mM)	-78 °C, 10 min	99	only
3	CH <sub>2</sub> Cl <sub>2</sub> (17 mM)	-78 °C, 10 min	88	1/24
4	EtCN (17 mM)	-78 °C, 10 min	97	only

**Table 5S.** The effect of anomeric configuration on the stereoselectivity of glycosidation of OFox donors **3** and **12**



Entry	Donor	Acceptor	Temp., time	Product, yield, %	/ ratio
1	<b>3</b> ( / = 10/1)	<b>4</b>	-78 °C, 5 min	<b>5</b> , 94	1/24
2	<b>-3</b>	<b>4</b>	-78 °C, 5 min	<b>5</b> , 98	1/24
3	$\alpha$ - <b>12</b>	<b>34</b>	rt, 15 min	<b>40</b> , 88	only
4	<b>-12</b>	<b>34</b>	rt, 15 min	<b>40</b> , 89	only

**Table 6S.** The effect of promoter on the stereoselectivity of glycosidation of per-benzylated OFox donor **3**




Entry	Promoter (equiv.)	Temp, time	Yield of <b>5</b> , %	/ ratio
1	TMSOTf (0.05 equiv.)	-78 °C, 5 min	94	1/24
2	TMSOTf (0.05 equiv.) <sup>a</sup>	-78 °C, 10 min	84	1/5.0
3	BF <sub>3</sub> -OEt <sub>2</sub> (0.1 equiv.)	-78 °C, 5 min	93	1/20
4	Cu(OTf) <sub>2</sub> (0.2 equiv.)	-78 °C, 5 min	97	only
5	MeOTf (0.2 equiv.)	-78 °C, 10 min	91	>1/25
6	AgOTf (0.5 equiv.)	rt, 24 h	71	1/1.6
7	PdCl <sub>2</sub> (0.3 equiv.)	rt, 36 h	57	1/1.7
8	TMSClO <sub>4</sub> (0.1 equiv.) <sup>a</sup>	rt, 10 min	75	5.0/1
9	TMSClO <sub>4</sub> (0.1 equiv.) <sup>b</sup>	rt, 5 min	54	6.2/1
10	Bi(OTf) <sub>3</sub> (0.1 equiv.)	-78 °C, 5 min	85	1/7

<sup>a</sup> - Et<sub>2</sub>O was used as the reaction solvent;

<sup>b</sup> - A mixture of Et<sub>2</sub>O/1,4-dioxane (1/1, v/v) was used as the reaction solvent

**Table 7S.** Comparative hydrolytic stability study of OFox, trichloro- and trifluoroacetimidates under various reaction conditions



For these studies, per-benzoylated OFox glycosyl donor **16** was compared with 2,3,4,6-tetra-*O*-benzoyl- *D*-glucopyranosyl trichloroacetimidate **23** and 2,3,4,6-tetra-*O*-benzoyl- , -*D*-glucopyranosyl *N*-phenyltrifluoroacetimidate **24**. These studies were performed in the presence of various Lewis acids in wet  $\text{ClCH}_2\text{CH}_2\text{Cl}$ . A mixture of imidate (**16**, **23**, or **24**, 0.01 mmol), promoter (A-D, see below, 0.013 mmol) in  $\text{ClCH}_2\text{CH}_2\text{Cl}/\text{H}_2\text{O}$  (0.5 mL, 500/1, v/v) was stirred for 24 h at rt. Quantitative estimates were made at 1, 16 and 24 h time points and are based on the accumulation of 2,3,4,6-tetra-*O*-benzoyl-*D*-glucopyranose **25**,<sup>1</sup> as observed by TLC ( $R_f = 0.45$ , ethyl acetate/hexanes, 3/7, v/v).

Entry	Donor	Conditions <sup>a</sup>	% of hemiacetal <b>25</b> formed after		
			1 h	16 h	24 h
1	<b>16</b>	A	quant.	quant.	quant.
2	<b>23</b>	A	50	60	60
3	<b>24</b>	A	40	50	50
4	<b>16</b>	B	0	0	0
5	<b>23</b>	B	0	0	0
6	<b>24</b>	B	0	0	0
7	<b>16</b>	C	0	quant.	quant.
8	<b>23</b>	C	0	0	20
9	<b>24</b>	C	0	0	0
10	<b>16</b>	D	0	0	50
11	<b>23</b>	D	0	10	quant.
12	<b>24</b>	D	0	70	quant.

<sup>a</sup> Conditions:

A:  $\text{BF}_3\text{-OEt}_2$  (0.1 equiv.);

B:  $\text{Bi}(\text{OTf})_3$  (0.1equiv.);














C: MeOTf (1.0 equiv.);

D:  $\text{PdCl}_2$  (0.1 equiv.)

**Table 8S.** TMSOTf-promoted glycosidation of OFox donor **3** with different acceptors in CH<sub>2</sub>Cl<sub>2</sub> or EtCN at -78 °C


Entry	Acceptor	Solvent	Product	Yield, % <sup>b</sup>	/ ratio <sup>c</sup>
1	2-propanol <b>26</b>	EtCN		77	only
2	<b>4</b>	CH <sub>2</sub> Cl <sub>2</sub>		94	1/24
3	<b>4</b>	EtCN	<b>5</b>	99	only
4	 <b>28</b>	CH <sub>2</sub> Cl <sub>2</sub>	 <b>29</b>	89	1/11
5	<b>28</b>	EtCN	<b>29</b>	87	1/18
6	 <b>30</b>	CH <sub>2</sub> Cl <sub>2</sub>	 <b>31</b>	85	1/12
7	<b>30</b>	EtCN	<b>31</b>	89	only
8	 <b>32</b>	CH <sub>2</sub> Cl <sub>2</sub>	 <b>33</b>	94	1/4.0
9	<b>32</b>	EtCN	<b>33</b>	92	1/12
10	 <b>34</b>	CH <sub>2</sub> Cl <sub>2</sub>	 <b>35</b>	90	1/6.0
11	<b>34</b>	EtCN	<b>35</b>	88	1/15
12	 <b>36</b>	CH <sub>2</sub> Cl <sub>2</sub>	 <b>37</b>	86	-only
13	 <b>38</b>	CH <sub>2</sub> Cl <sub>2</sub>	 <b>39</b>	88	1/23

**Table 9S.** Glycosylation with per-acetylated glucosyl, galactosyl, and mannosyl OFox donors in CH<sub>2</sub>Cl<sub>2</sub> with TMSOTf as a promoter at rt.

Entry	Donor	Acceptor	Product	Yield, %
1 <sup>a</sup>		4		80
2		4		94
3	16	28		86
4	16	30		90
5	16	32		93
6		4		98
7	18	30		98
9		4		93
10	20	30		90

<sup>a</sup> – SnCl<sub>4</sub> was used as a promoter to prevent acetyl migration to the C-6 of acceptor that was observed in the presence of TMSOTf.



**Table 10S.** Regenerative glycosylation, a complete experimental dataset



Entry	Donor	Acceptor	HOFox (equiv.)	Reaction time	Product	Yield	Ratio /
1			0	5 h		9%	1/1.1
2	<b>6</b>	<b>4</b>	0.10	3 h	<b>5</b>	84%	1/1.9
3	<b>6</b>	<b>4</b>	0.25	2 h	<b>5</b>	79%	1/1.9
4	<b>6</b>	<b>4</b>	0.50	40 min	<b>5</b>	86%	1/1.2
5	<b>6</b>	<b>4</b>	0.75	30 min	<b>5</b>	88%	1/1.2
6	<b>6</b>	<b>4</b>	1.0	10 min	<b>5</b>	90%	1/1.2
7	<b>6</b>		0.1	3 h		72%	1/1.7
8	<b>6</b>		0.25	3 h		62%	1/1.0
9		<b>4</b>	0.1	2.5 h		69%	1/1.1
10		<b>4</b>	0.1	3 h		75%	2.5/1



**Scheme 1S.** “Regenerative glycosylation” experiment performed in the NMR tube with bromide donor **7**, HOFox (0.25 equiv.), Ag<sub>2</sub>O (3.0 equiv.) in CD<sub>2</sub>Cl<sub>2</sub> at 0 °C in the absence of a glycosyl acceptor



## General Experimental Remarks

All reactions were performed under argon with dry, freshly distilled solvents unless otherwise noted. CH<sub>2</sub>Cl<sub>2</sub>, ClCH<sub>2</sub>CH<sub>2</sub>Cl, toluene, CH<sub>3</sub>CN, and EtCN were distilled from CaH<sub>2</sub> directly prior to application. Anhydrous 1,4-dioxane, tetrahydrofuran, and diethyl ether were used as is. AgOTf was co-evaporated with toluene (3 x 10 mL) and dried in *vacuo* for 2-3 h directly prior to application. TMSOTf, SnCl<sub>4</sub>, MeOTf, BF<sub>3</sub>-OEt<sub>2</sub>, Cu(OTf)<sub>2</sub>, PdCl<sub>2</sub>, TMSClO<sub>4</sub> and Bi(OTf)<sub>3</sub> were used as is. Molecular sieves (3 Å or 4 Å), used for the reactions, were crushed and activated at 390 °C and then for 2-3 h at 390 °C prior to application. Reactions were monitored by TLC on Kieselgel 60 F<sub>254</sub> and the compounds were detected by examination under UV light and by charring with 10% sulfuric acid in methanol. Solvents were removed under reduced pressure at < 40 °C. Column chromatography was performed on silica gel 60 (70-230 mesh). Optical rotations were measured at 'Jasco P-1020' polarimeter. <sup>1</sup>H n.m.r. spectra were recorded at 300 MHz, 500 MHz, or 600 MHz. <sup>13</sup>C n.m.r. spectra were recorded at 75 MHz or 150 MHz. <sup>19</sup>F spectra were recorded at 282.2 MHz. The <sup>1</sup>H chemical shifts are referenced to the signal of the residual CHCl<sub>3</sub> ( <sub>H</sub> = 7.27 ppm) for solutions in CDCl<sub>3</sub>. The <sup>13</sup>C chemical shifts are referenced to the central signal of CDCl<sub>3</sub> ( <sub>C</sub> = 77.23 ppm) for solutions in CDCl<sub>3</sub>. HRMS determinations were made with the use of JOEL MStation (JMS-700) Mass Spectrometer.

## Synthesis of 3,3-difluoroxindole (HOFox, 3,3-difluoroindolin-2-one)



The title compound was obtained from isatin and DAST as previously described. Analytical data were in accordance with that previously reported.<sup>2</sup>


## Preparation of OFox imidates

**Method A. A typical procedure for the preparation from hemiacetals via glycosyl chlorides.** SOCl<sub>2</sub> (81.1 μL, 1.11 mmol) was added dropwise to a solution of hemiacetal (**8** or **9**, 0.20 g, 0.37 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (2.0 mL) and dry DMF (14.3 μL) and the resulting mixture was stirred under argon for 7 h at rt. Upon completion, the reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (~30 mL) and washed with sat. aq. NaHCO<sub>3</sub> (2 x 15 mL) and cold water (2 x 15 mL). The organic phase was separated, dried with MgSO<sub>4</sub>, and concentrated *in vacuo*. The residue containing crude glycosyl halide (0.37 mmol) was dried under high vacuum for 4 h. Freshly activated molecular sieves (3 Å, 600 mg) and dry CH<sub>2</sub>Cl<sub>2</sub> (2.0 mL) were added and the resulting mixture was stirred under argon for 1 h at rt. After that, 3,3-difluoroxindole (69 mg, 0.41 mmol), Ag<sub>2</sub>O (258 mg, 1.11 mmol), and diisopropylethylamine (DIPEA, 97 μL, 0.56 mmol) were added and the resulting mixture was stirred for 8-12 h. The solids were filtered off through a pad of Celite and rinsed successively with CH<sub>2</sub>Cl<sub>2</sub>. The combined filtrate (~40 mL) was washed with 1% aq. NaOH (2 x 15 mL) and water (2 x 15 mL). The organic phase was separated, dried with MgSO<sub>4</sub>, and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (ethyl acetate-hexanes gradient elution) to afford the corresponding OFox imidates **3** or **10** in yields listed in Table 1S.

**Methods B and C. A typical procedure for the preparation from glycosyl bromides.** A mixture of a glycosyl bromide (**11**, **13**, **15** or **21**, 0.15 mmol) and freshly activated molecular sieves (3 Å, 300 mg) in dry CH<sub>2</sub>Cl<sub>2</sub> (Method B, 1.0 mL) or toluene (Method C, 1.0 mL) was stirred under argon for 1 h at rt. After that, 3,3-difluorooxindole (25.7 mg, 0.15 mmol), Ag<sub>2</sub>O (105 mg, 0.45 mmol), and DIPEA (39.7 μL, 0.23 mmol) were added and the resulting mixture was stirred for 40 min-10 h at the temperature indicated in Table 1S. The solids were filtered off through a pad of Celite and rinsed successively with CH<sub>2</sub>Cl<sub>2</sub>. The combined filtrate (~40 mL) was washed with 1% aq. NaOH (2 x 15 mL) and water (2 x 15 mL). The organic phase was separated, dried with MgSO<sub>4</sub>, and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (ethyl acetate-hexanes gradient elution) to afford the corresponding OFox imidates in yields listed in Table 1S.


**Method D. A typical procedure for the preparation from pentabenzoates via glycosyl bromides.** A 33% solution of HBr in AcOH (0.10 mL, 1.7 mmol) was added to a solution of a 1,2,3,4,6-penta-*O*-benzoyl-D-galacto or mannopyranose (**17** or **19**, 100 mg, 0.14 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (0.2 mL) and the resulting mixture was stirred under argon for 2-4 h at rt. The reaction mixture was then diluted with CH<sub>2</sub>Cl<sub>2</sub> (~40 mL) and washed with cold sat. aq. NaHCO<sub>3</sub> (2 x 15 mL) and cold water (2 x 15 mL). The organic phase was separated, dried with MgSO<sub>4</sub>, and concentrated *in vacuo*. The residue containing crude glycosyl bromide (0.14 mmol) was dried under high vacuum for 4 h. After that, freshly activated molecular sieves (3 Å) and dry CH<sub>2</sub>Cl<sub>2</sub> (1.4 mL) were added and the resulting mixture was stirred under argon for 1 h at rt. After that, the resulting mixture was cooled to 0 °C in case of galactose sugar and at rt for mannose sugar, followed by addition of 3,3-difluorooxindole (26.7 mg, 0.16 mmol), Ag<sub>2</sub>O (99.2 mg, 0.43 mmol) and DIPEA (37.4 μL, 0.21 mmol) were added and the resulting mixture was stirred for 2-6 h as indicated in Table 1S. The solids were then filtered off through a pad of Celite and rinsed successively with CH<sub>2</sub>Cl<sub>2</sub>. The combined filtrate (~40 mL) was washed with 1% aq. NaOH (2 x 15 mL) and water (2 x 15 mL). The organic phase was separated, dried with MgSO<sub>4</sub>, and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (ethyl acetate-hexanes gradient elution) to afford the corresponding OFox imidates in yields listed in Table 1S.

### 3,3-Difluoro-3*H*-indol-2-yl 2,3,4,6-tetra-*O*-benzyl- / -D-glucopyranoside (**3**)




The title compound was obtained from 2,3,4,6-tetra-*O*-benzyl-D-glucopyranose **8**<sup>3</sup> by Method B in 62% yield ( / = 10/1) as a white foam. Analytical data for **-3**: R<sub>f</sub> = 0.43 (ethyl acetate/hexanes, 1/4, v/v); <sup>1</sup>H n.m.r. (300 MHz): , 3.66 (dd, 1H, J<sub>5,6a</sub> = 1.8 Hz, J<sub>6a,6b</sub> = 10.9 Hz, H-6a), 3.79 (dd, 1H, J<sub>2,3</sub> = 9.3 Hz, H-2, ), 3.79 (dd, 1H, J<sub>5,6b</sub> = 3.3 Hz, H-6b), 3.83 (dd, 1H, J<sub>4,5</sub> = 9.3 Hz, H-4), 4.01 (m, 1H, H-5), 4.13 (dd, 1H, J<sub>3,4</sub> = 9.3 Hz, H-3), 4.52 (dd, 2H, <sup>2</sup>J = 12.0 Hz, CH<sub>2</sub>Ph), 4.69 (dd, 2H, <sup>2</sup>J = 10.5 Hz, CH<sub>2</sub>Ph), 4.73 (s, 2H, CH<sub>2</sub>Ph), 4.93 (dd, 2H, <sup>2</sup>J = 10.9 Hz, CH<sub>2</sub>Ph), 6.50 (d, 1H, J<sub>1,2</sub> = 3.3 Hz, H-1), 7.11-7.42 (m, 24H, aromatic) ppm; <sup>13</sup>C n.m.r. (75 MHz): , 68.1, 73.2, 73.5, 73.6 (x 2), 75.2, 75.3, 79.4, 81.5, 99.8, 117.4, 120.4, 123.3, 125.7, 127.8, 127.9, 128.0 (x 4), 128.0 (x 2), 128.1 (x 7), 128.6 (x 8), 133.6, 137.9, 138.0, 138.2, 138.8 ppm; <sup>19</sup>F n.m.r.: , -121.3 (s, 2F, CF<sub>2</sub>) ppm; HR-FAB MS [M+Na]<sup>+</sup> calculated for C<sub>42</sub>H<sub>39</sub>F<sub>2</sub>NO<sub>6</sub>Na<sup>+</sup> 714.2643, found 714.2645.

### 3,3-Difluoro-3*H*-indol-2-yl 2,3,4,6-tetra-*O*-benzyl- -D-mannopyranoside (**10**)




The title compound was obtained from 2,3,4,6-tetra-*O*-benzyl- / -D-mannopyranose **9**<sup>4</sup> by Method A in 61% yield as a white foam. Analytical data for **10**:  $R_f = 0.45$  (ethyl acetate/hexanes, 2/3, v/v);  $[\alpha]_D^{24} +13.7$  ( $c = 1.0$ ,  $\text{CHCl}_3$ );  $^1\text{H}$  n.m.r. (300 MHz):  $\delta$ , 3.74 (dd, 1H,  $J_{5,6a} = 1.8$  Hz,  $J_{6a,6b} = 11.3$  Hz, H-6a), 3.84 (dd, 1H,  $J_{5,6b} = 4.3$  Hz, H-6b), 3.95-4.03 (m, 3H, H-2, 4, 5), 4.14 (m, 1H,  $J_{3,4} = 9.5$  Hz, H-3), 4.60 (dd, 2H,  $^2J = 11.6$  Hz,  $\text{CH}_2\text{Ph}$ ), 4.62 (dd, 2H,  $^2J = 12.1$  Hz,  $\text{CH}_2\text{Ph}$ ), 4.70 (dd, 2H,  $^2J = 10.7$  Hz,  $\text{CH}_2\text{Ph}$ ), 4.78 (s, 2H,  $\text{CH}_2\text{Ph}$ ), 6.40 (d, 1H,  $J_{1,2} = 1.1$  Hz, H-1), 7.15-7.47 (m, 24H, aromatic) ppm;  $^{13}\text{C}$  n.m.r. (75 MHz):  $\delta$ , 69.1, 72.6, 72.8, 73.1, 73.4, 74.0, 74.8, 75.3, 79.0, 97.7, 120.5 (x 2), 123.4 (x 2), 125.9, 126.7, 127.7, 127.7 (x 2), 128.0 (x 3), 128.1 (x 2), 128.2 (x 2), 128.3 (x 3), 128.5 (x 2), 128.6 (x 6), 133.7, 138.0, 138.2, 138.4 (x 2), ppm;  $^{19}\text{F}$  n.m.r.:  $\delta$ , -121.5 (s, 2F,  $\text{CF}_2$ ) ppm; HR-FAB MS  $[\text{M}+\text{Na}]^+$  calculated for  $\text{C}_{42}\text{H}_{39}\text{F}_2\text{NO}_6\text{Na}^+$  714.2643, found 714.2639.

### 3,3-Difluoro-3*H*-indol-2-yl 3,4,6-tri-*O*-acetyl-2-*O*-benzyl- -D-glucopyranoside (**12**)



The title compound was obtained from 3,4,6-tri-*O*-acetyl-2-*O*-benzyl- -D-glucopyranosyl bromide **11** by Method B at rt in 80% yield as a white foam. Analytical data for **12**:  $R_f = 0.39$  (ethyl acetate/hexanes, 2/3, v/v);  $[\alpha]_D^{26} +13.7$  ( $c = 1.0$ ,  $\text{CHCl}_3$ );  $^1\text{H}$  n.m.r. (300 MHz):  $\delta$ , 1.95, 2.03, 2.07 (3s, 9H, 3 x  $\text{COCH}_3$ ), 3.80 (dd, 1H,  $J_{2,3} = 7.9$  Hz, H-2), 3.95 (m, 1H, H-5), 4.14 (dd, 1H,  $J_{5,6a} = 2.3$  Hz,  $J_{6a,6b} = 12.5$  Hz, H-6a), 4.34 (dd, 1H,  $J_{5,6b} = 4.4$  Hz, H-6b), 4.74 (dd, 2H,  $^2J = 11.6$  Hz,  $\text{CH}_2\text{Ph}$ ), 5.11 (dd, 1H,  $J_{4,5} = 9.5$  Hz, H-4), 5.27 (dd, 1H,  $J_{3,4} = 9.2$  Hz, H-3), 5.94 (d, 1H,  $J_{1,2} = 7.8$  Hz, H-1), 7.18-7.49 (m, 9H, aromatic) ppm;  $^{13}\text{C}$  n.m.r. (75 MHz):  $\delta$ , 20.7 (x 2), 20.8, 61.5, 67.9, 72.6, 73.6, 74.7, 77.6, 99.1, 120.6, 123.3, 126.2, 128.1 (x 2), 128.3 (x 3), 128.5 (x 3), 133.7, 137.1, 150.3, 169.7, 170.0, 170.7 ppm;  $^{19}\text{F}$  n.m.r.:  $\delta$ , -122.0 (d, 2F,  $\text{CF}_2$ ) ppm; HR-FAB MS  $[\text{M}+\text{Na}]^+$  calculated for  $\text{C}_{27}\text{H}_{27}\text{F}_2\text{NO}_9\text{Na}^+$  570.1552, found 570.1562.


### 3,3-Difluoro-3*H*-indol-2-yl 3,4,6-tri-*O*-acetyl-2-*O*-benzyl- -D-glucopyranoside ( $\alpha$ -**12**)



The title compound was obtained from 3,4,6-tri-*O*-acetyl-2-*O*-benzyl- -D-glucopyranosyl bromide **11** by Method B at 0 °C in 81% yield as a white foam. Analytical data for  $\alpha$ -**12**:  $R_f = 0.38$  (ethyl acetate/hexanes, 2/3, v/v);  $[\alpha]_D^{25} +101.4$  ( $c = 1.0$ ,  $\text{CHCl}_3$ );  $^1\text{H}$  n.m.r. (300 MHz):  $\delta$ , 2.02, 2.03, 2.05 (3s, 9H, 3 x  $\text{COCH}_3$ ), 3.81 (dd, 1H,  $J_{2,3} = 9.9$  Hz, H-2), 4.06 (dd, 1H,  $J_{5,6a} = 2.0$  Hz,  $J_{6a,6b} = 12.4$  Hz, H-6a), 4.18 (m, 1H, H-5), 4.29 (dd, 1H,  $J_{5,6b} = 4.1$  Hz, H-6b), 4.67 (s, 2H,  $\text{CH}_2\text{Ph}$ ), 5.11 (dd, 1H,  $J_{4,5} = 10.0$  Hz, H-4), 5.57 (d, 1H,  $J_{3,4} = 9.7$  Hz, H-3), 6.45 (d, 1H,  $J_{1,2} = 3.5$  Hz, H-1), 7.17-7.40 (m, 9H, aromatic) ppm;  $^{13}\text{C}$  n.m.r. (75 MHz):  $\delta$ , 20.7 (x 2), 20.8, 61.4, 67.8, 69.8, 71.4, 73.3, 75.7, 95.0, 120.4, 123.3, 125.9, 126.8, 127.9 (x 3), 128.2, 128.6 (x 3),


133.5, 137.2, 150.4, 168.7, 169.8, 170.1 ppm;  $^{19}\text{F}$  n.m.r.: , -121.6 (s, 1F,  $\text{CF}_2^{\text{a}}$ ), -121.5 (s, 1F,  $\text{CF}_2^{\text{b}}$ ); HR-FAB MS  $[\text{M}+\text{Na}]^+$  calculated for  $\text{C}_{27}\text{H}_{27}\text{F}_2\text{NO}_9\text{Na}^+$  570.1552, found 570.1569.

### 3,3-Difluoro-3*H*-indol-2-yl 2,3,4,6-tetra-*O*-acetyl- -D-glucopyranoside (14)




The title compound was obtained from 2,3,4,6-tetra-*O*-acetyl- -D-glucopyranosyl bromide **13**<sup>5</sup> by Method C in 62% yield as a white foam. Analytical data for **14**:  $R_f = 0.42$  (ethyl acetate/hexanes, 1/1, v/v);  $[\alpha]_{\text{D}}^{21} +5.2$  ( $c = 1.0$ ,  $\text{CHCl}_3$ );  $^1\text{H}$  n.m.r. (300 MHz): , 1.96, 1.97, 1.98, 2.01 (4s, 12H, 4 x  $\text{COCH}_3$ ), 3.95 (m, 1H, H-5), 4.15 (dd, 1H,  $J_{5,6a} = 2.3$  Hz,  $J_{6a,6b} = 12.5$  Hz, H-6a), 4.30 (dd, 1H,  $J_{5,6b} = 4.3$  Hz, H-6b), 5.17-5.32 (m, 3H, H-2, 3, 4), 5.95 (m, 1H, H-1), 7.14-7.40 (m, 4H, aromatic) ppm;  $^{13}\text{C}$  n.m.r. (75 MHz): , 20.4, 20.6 (x 2), 20.7, 61.4, 67.6, 70.3, 72.4, 72.9, 96.6, 120.5 (x 2), 123.3 (x 2), 126.2, 126.8, 133.6, 150.0, 169.3, 169.4, 170.2, 170.8 ppm;  $^{19}\text{F}$  n.m.r.: , -122.4 (s, 1F,  $\text{CF}_2^{\text{a}}$ ), -122.3 (s, 1F,  $\text{CF}_2^{\text{b}}$ ) ppm; HR-FAB MS  $[\text{M}+\text{H}]^+$  calculated for  $\text{C}_{22}\text{H}_{23}\text{F}_2\text{NO}_{10}$  500.1290, found 500.1361.

### 3,3-Difluoro-3*H*-indol-2-yl 2,3,4,6-tetra-*O*-benzoyl- -D-glucopyranoside (16)



The title compound was obtained from 2,3,4,6-tetra-*O*-benzoyl- -D-glucopyranosyl bromide **15**<sup>6</sup> by Method B in 75% yield as a pale yellow foam. Analytical data for **16**:  $R_f = 0.41$  (ethyl acetate/hexanes, 3/7, v/v);  $[\alpha]_{\text{D}}^{23} +45.8$  ( $c = 1.0$ ,  $\text{CHCl}_3$ );  $^1\text{H}$  n.m.r. (300 MHz): , 4.48 (dd, 1H,  $J_{5,6a} = 4.7$  Hz,  $J_{6a,6b} = 12.4$  Hz, H-6a), 4.64 (m, 2H,  $J_{5,6b} = 2.3$  Hz, H-5, 6b), 5.69 (dd, 1H,  $J_{2,3} = 10.2$  Hz, H-2), 5.83 (dd, 1H,  $J_{4,5} = 10.0$  Hz, H-4), 6.31 (dd, 1H,  $J_{3,4} = 10.0$  Hz, H-3), 6.82 (d, 1H,  $J_{1,2} = 3.7$  Hz, H-1), 7.05-7.99 (m, 24H, aromatic) ppm;  $^{13}\text{C}$  n.m.r. (75 MHz): , 62.4, 68.6, 70.1, 70.3, 70.6, 94.8, 120.6, 123.2, 126.0, 126.5, 128.3, 128.4 (x 2), 128.4 (x 2), 128.5 (x 4), 128.6 (x 2), 128.8, 129.1, 129.5, 129.7 (x 2), 129.8 (x 2), 130.0 (x 4), 133.1, 133.4, 133.5, 133.6, 133.7, 150.1, 165.2, 165.5, 165.6, 166.0 ppm;  $^{19}\text{F}$  n.m.r.: , -121.8 (s, 1F,  $\text{CF}_2^{\text{a}}$ ), -121.6 (s, 1F,  $\text{CF}_2^{\text{b}}$ ) ppm; HR-FAB MS  $[\text{M}+\text{Na}]^+$  calculated for  $\text{C}_{42}\text{H}_{31}\text{F}_2\text{NO}_{10}\text{Na}^+$  770.1813, found 770.1800.


### 3,3-Difluoro-3*H*-indol-2-yl 2,3,4,6-tetra-*O*-benzoyl- -D-galactopyranoside (18)



This compound was obtained from 2,3,4,6-tetra-*O*-benzoyl- -D-galactopyranosyl bromide **17**<sup>7</sup> by Method D in 75% yield as a white foam. Analytical data for **18**:  $R_f = 0.39$  (ethyl acetate/hexanes, 3/7, v/v);  $[\alpha]_{\text{D}}^{22} +2.7$  ( $c = 1.0$ ,  $\text{CHCl}_3$ );  $^1\text{H}$  n.m.r. (300 MHz): , 4.51 (dd, 1H,  $J_{5,6a} = 5.9$  Hz,  $J_{6a,6b} = 10.6$  Hz, H-6a), 4.63 (m, 1H, H-5), 4.72 (dd, 1H,  $J_{5,6b} = 6.6$  Hz, H-6b), 5.75 (dd, 1H,  $J_{3,4} = 3.4$  Hz, H-3), 6.11 (m, 2H, H-2, 4), 6.34 (d, 1H,  $J_{1,2} = 7.8$  Hz, H-1), 7.14-8.14 (m, 24H, aromatic) ppm;  $^{13}\text{C}$  n.m.r. (75 MHz): , 61.8, 67.6, 68.9, 71.4, 72.7, 97.4, 120.4, 123.6, 124.7, 125.4, 128.3, 128.6 (x 4), 128.7, 128.8, 128.9 (x 2), 129.0, 129.2 (x 2), 129.4, 129.9 (x 9),


130.1 (x 2), 133.3, 133.5, 133.6, 133.8, 165.1, 165.5 (x 2), 166.0 ppm;  $^{19}\text{F}$  n.m.r.: , -122.2 (s, 2F,  $\text{CF}_2$ ); HR-FAB MS  $[\text{M}+\text{Na}]^+$  calculated for  $\text{C}_{42}\text{H}_{31}\text{F}_2\text{NO}_{10}\text{Na}^+$  770.1813, found 770.1791.

### 3,3-Difluoro-3*H*-indol-2-yl 2,3,4,6-tetra-*O*-benzoyl- -*D*-mannopyranoside (20)



The title compound was obtained from 2,3,4,6-tetra-*O*-benzoyl- -*D*-mannopyranosyl bromide **19**<sup>8</sup> by Method D in 84% yield as a white foam. Analytical data for **20**:  $R_f = 0.43$  (ethyl acetate/hexanes, 3/7, v/v);  $[\alpha]_{\text{D}}^{21} -5.3$  ( $c = 1.0$ ,  $\text{CHCl}_3$ );  $^1\text{H}$  n.m.r. (300 MHz): , 4.52 (dd, 1H,  $J_{5,6a} = 4.4$  Hz,  $J_{6a,6b} = 12.1$  Hz, H-6a), 4.62 (m, 1H, H-5), 4.70 (dd, 1H,  $J_{5,6b} = 2.2$  Hz, H-6b), 6.02 (dd, 1H,  $J_{2,3} = 3.3$  Hz, H-2), 6.07 (dd, 1H,  $J_{3,4} = 10.0$  Hz, H-3), 6.24 (dd, 1H,  $J_{4,5} = 10.0$  Hz, H-4), 6.64 (d, 1H,  $J_{1,2} = 1.7$  Hz, H-1), 7.16-8.09 (m, 24H, aromatic) ppm;  $^{13}\text{C}$  n.m.r. (75 MHz): , 62.5, 66.2, 69.0, 69.6, 71.5, 96.0, 121.0, 123.5, 125.5, 126.4, 126.8, 128.4, 128.5 (x 2), 128.6 (x 2), 128.7 (x 2), 128.8, 128.9 (x 2), 128.9, 129.0, 129.2, 129.8, 129.9 (x 2), 130.0 (x 2), 130.1 (x 4), 133.2, 133.6, 133.8, 134.0, 138.1, 165.2, 165.5, 165.6, 166.1 ppm;  $^{19}\text{F}$  n.m.r.: , -121.8 (s, 1F,  $\text{CF}_2^a$ ), -121.5 (s, 1F,  $\text{CF}_2^b$ ); HR-FAB MS  $[\text{M}+\text{Na}]^+$  calculated for  $\text{C}_{42}\text{H}_{31}\text{F}_2\text{NO}_{10}\text{Na}^+$  770.1813, found 770.1814.


### 3,3-Difluoro-3*H*-indol-2-yl 3,4,6-tri-*O*-acetyl-2-azido-2-deoxy- -*D*-glucopyranoside (22)



The title compound was obtained from 3,4,6-tri-*O*-acetyl-2-azido-2-deoxy- -*D*-glucopyranosyl bromide **21** by Method B in 70% yield as a white foam. Analytical data for **22**:  $R_f = 0.43$  (ethyl acetate/hexanes, 2/3, v/v);  $[\alpha]_{\text{D}}^{24} +8.4$  ( $c = 1.0$ ,  $\text{CHCl}_3$ );  $^1\text{H}$  n.m.r. (300 MHz): , 2.05, 2.08, 2.12 (3s, 9H, 3 x  $\text{COCH}_3$ ), 3.88 (dd, 1H,  $J_{2,3} = 9.2$  Hz, H-2), 3.93 (m, 1H, H-5), 4.16 (dd, 1H,  $J_{5,6a} = 2.3$  Hz, H-6a), 4.35 (dd, 1H,  $J_{5,6b} = 4.3$  Hz,  $J_{6a,6b} = 12.6$  Hz, H-6b), 5.13 (dd, 1H,  $J_{4,5} = 8.9$  Hz, H-4), 5.17 (dd, 1H,  $J_{3,4} = 9.2$  Hz, H-3), 5.82 (d, 1H,  $J_{1,2} = 8.3$  Hz, H-1), 7.19-7.43 (m, 4H, aromatic) ppm;  $^{13}\text{C}$  n.m.r. (75 MHz): , 20.7, 20.8, 20.9, 60.6, 63.1, 67.8, 72.7, 73.0, 97.6, 120.7, 123.5, 126.5, 126.7, 127.0, 127.3, 133.8, 150.1, 169.8, 170.0, 170.7 ppm;  $^{19}\text{F}$  n.m.r.: , -122.2 (s, 2F,  $\text{CF}_2$ ). HR-FAB MS  $[\text{M}+\text{Na}]^+$  calculated for  $\text{C}_{20}\text{H}_{20}\text{F}_2\text{N}_4\text{O}_8\text{Na}^+$  505.1147, found 505.1142.

## Preparation and characterization of other glycosyl donors and intermediates


### 2,3,4,6-Tetra-*O*-benzyl- / -*D*-glucopyranosyl trichloroacetimidate (1)



This compound was obtained from 2,3,4,6-tetra-*O*-benzyl-*D*-glucopyranose **8**<sup>3</sup> in 62% yield as a white foam as previously described.<sup>9</sup> Analytical data for is this for **1**:  $R_f = 0.43$  (ethyl acetate/hexanes, 1/4 v/v);  $^1\text{H}$  n.m.r. (300 MHz): , 3.67 (dd, 1H,  $J_{5,6a} = 1.9$  Hz,  $J_{6a,6b} = 10.9$  Hz, H-6a), 3.74-3.80 (m, 3H, H-2, 4, 6b), 3.99 (m, 1H, H-5), 4.05 (dd, 1H,  $J_{3,4} = 9.4$  Hz, H-3), 4.53 (dd, 2H,  $^2J = 12.0$  Hz,  $\text{CH}_2\text{Ph}$ ), 4.71 (dd, 2H,  $^2J = 11.7$  Hz,  $\text{CH}_2\text{Ph}$ ), 4.73 (dd, 2H,  $^2J = 10.7$  Hz,


$CH_2Ph$ ), 4.84 (dd, 2H,  $^2J = 7.6$  Hz,  $CH_2Ph$ ), 6.50 (d, 1H,  $J_{1,2} = 3.4$  Hz, H-1), 7.12-7.33 (m, 24H, aromatic), 8.57 (s, 1H, NH) ppm;  $^{13}C$  n.m.r. (75 MHz): , 68.1, 73.0, 73.2, 73.6, 75.5, 75.8, 79.5, 81.5, 91.4, 94.5, 127.8 (x 3), 127.9 (x 2), 128.0, 128.1 (x 2), 128.2 (x 4), 128.5 (x 4), 128.6 (x 4), 137.9, 138.1, 138.2, 138.7, 161.4 ppm; HR-ESI MS  $[M+Na]^+$  calculated for  $C_{36}H_{36}Cl_3NO_6Na^+$  706.1506, found 706.1500.

### 2,3,4-Tri-*O*-benzyl-, -*D*-glucopyranosyl *N*-phenyltrifluoroacetimidate (2)




The title compound was obtained from 2,3,4,6-tetra-*O*-benzyl-*D*-glucopyranose **8**<sup>3</sup> by adapting previously published procedure.<sup>10</sup> 2,2,2-Trifluoro-*N*-phenylethanimidoyl chloride (89.4  $\mu$ L, 0.55 mmol) and  $K_2CO_3$  (55 mg, 0.55 mmol) were added to a solution of **8** (150 mg, 0.28 mmol) in acetone (1.5 mL) and the resulting mixture was stirred for 3 h at rt. The solids were filtered off through a pad of Celite and the filtrate was concentrated in *vacuo*. The residue was purified by column chromatography on silica gel (ethyl acetate-hexanes gradient elution) to afford the title compound in 72% yield as a white amorphous solid. Analytical data for **2**:  $R_f = 0.5$  (ethyl acetate/hexanes, 1/4, v/v);  $^1H$  n.m.r. (500 MHz): , 3.56-3.95 (m, 6H, H-2, 3, 4, 5, 6a, 6b), 4.58 (dd, 2H,  $^2J = 9.5$  Hz,  $CH_2Ph$ ), 4.69 (dd, 2H,  $^2J = 12.2$  Hz,  $CH_2Ph$ ), 4.88 (s, 2H,  $CH_2Ph$ ), 5.00 (dd, 2H,  $^2J = 10.2$  Hz,  $CH_2Ph$ ), 5.74 (d, 1H,  $J_{1,2} = 8.0$  Hz, H-1), 6.78-7.5 (m, 25H, aromatic);  $^{13}C$  n.m.r. (75 MHz): , 73.6, 75.3, 75.4, 75.8 (x 2), 75.9 (x 2), 75.8, 81.1, 84.7, 119.5, 124.5, 127.9, 128.0 (x 2), 128.1 (x 3), 128.2 (x 3), 128.4 (x 2), 128.6 (x 6), 128.7 (x 7), 128.9 (x 2), 137.9, 138.1 (x 2), 138.5, 143.6 ppm; HR-FAB MS  $[M+Na]^+$  calculated for  $C_{42}H_{40}F_3NO_6Na^+$  734.2705, found 734.2720.

### Ethyl 2,3,4,6-tetra-*O*-benzyl-1-thio- -*D*-glucopyranoside (6)




The title compound was obtained as previously described.<sup>11</sup>

### 3,4,6-Tri-*O*-acetyl-2-*O*-benzyl- -*D*-glucopyranosyl bromide (11)




The title compound was obtained from 1,3,4,6-tetra-*O*-acetyl-2-*O*-benzyl-*D*-glucopyranose<sup>12</sup> in 90% yield as a white foam as previously described.<sup>13</sup> Analytical data for **11**:  $R_f = 0.43$  (ethyl acetate/hexanes, 2/3, v/v);  $^1H$  n.m.r. (300 MHz): , 1.96, 1.98, 2.00 (3s, 9H, 3 x  $COCH_3$ ), 3.57 (dd, 1H,  $J_{2,3} = 9.6$  Hz, H-2), 4.12 (m, 1H,  $J_{5,6a} = 4.1$  Hz, H-6a), 4.22 (m, 1H, H-5), 4.27 (dd, 1H,  $J_{5,6b} = 4.0$  Hz,  $J_{6a,6b} = 12.6$  Hz, 6b), 4.63 (dd, 2H,  $^2J = 12.3$  Hz,  $CH_2Ph$ ), 5.06 (dd, 1H,  $J_{4,5} = 9.8$  Hz, H-4), 5.48 (dd, 1H,  $J_{3,4} = 9.5$  Hz, H-3), 6.34 (d, 1H,  $J_{1,2} = 3.9$  Hz, H-1) ppm;  $^{13}C$  n.m.r. (75 MHz): , 20.8, 20.9 (x 2), 61.3, 67.3, 72.2 (x 2), 72.9, 76.5, 89.2, 128.1 (x 2), 128.5, 128.8 (x 2), 137.0, 169.9, 170.1, 170.7 ppm; HR-FAB MS  $[M+Na]^+$  calculated for  $C_{19}H_{23}BrO_8Na^+$  481.0474, found 481.0483.

### 2,3,4,6-Tetra-*O*-benzoyl- -D-galactopyranosyl bromide (15)




The title compound was obtained from 1,2,3,4,6-penta-*O*-benzoyl-D-galactopyranose in 90% yield as a white foam as previously described.<sup>14</sup> Analytical data for **15**:  $R_f = 0.44$  (ethyl acetate/hexanes, 3/7, v/v);  $[\alpha]_D^{21} +152.5$  ( $c = 1.0$ ,  $\text{CHCl}_3$ );  $^1\text{H}$  n.m.r. (300 MHz):  $\delta$ , 4.47 (dd, 1H,  $J_{5,6b} = 6.0$  Hz,  $J_{6a,6b} = 11.6$  Hz, H-6b), 4.65 (dd, 1H,  $J_{5,6a} = 6.8$  Hz, H-6a), 4.93 (dd, 1H, H-5), 5.67 (dd, 1H,  $J_{2,3} = 9.8$  Hz, H-2), 6.06 (dd, 1H,  $J_{3,4} = 10.0$  Hz, H-3), 6.13 (dd, 1H,  $J_{4,5} = 3.8$  Hz, H-4), 6.98 (d, 1H,  $J_{1,2} = 4.0$  Hz, H-1) ppm;  $^{13}\text{C}$  n.m.r. (75 MHz):  $\delta$ , 61.9, 68.3, 68.8, 69.1, 72.0, 88.5, 128.6 (x 2), 128.7 (x 2), 128.7, 128.8 (x 2), 128.9 (x 2), 129.0 (x 2), 129.4, 130.0 (x 4), 130.2 (x 4), 133.6 (x 2), 134.0 (x 2), 165.5, 165.6, 165.8, 166.1 ppm; HR-FAB MS  $[\text{M}+\text{Na}]^+$  calculated for  $\text{C}_{34}\text{H}_{27}\text{BrO}_9\text{Na}^+$  681.0736, found 681.0721.

### 3,4,6-Tri-*O*-acetyl-2-azido-2-deoxy- -D-glucopyranosyl bromide (21)




The title compound was obtained from 1,3,4,6-tetra-*O*-acetyl-2-azido-2-deoxy-D-glucopyranose<sup>15,16</sup> in 90% yield as a white foam as previously described.<sup>17,18</sup> Analytical data for **21**:  $R_f = 0.46$  (ethyl acetate/hexanes, 2/3, v/v);  $[\alpha]_D^{19} +146.9$  ( $c = 1.0$ ,  $\text{CHCl}_3$ );  $^1\text{H}$  n.m.r. (300 MHz):  $\delta$ , 2.06, 2.09, 2.11 (3s, 9H, 3 x  $\text{COCH}_3$ ), 3.81 (dd, 1H,  $J_{2,3} = 10.2$  Hz, H-2), 4.12 (m, 1H,  $J_{5,6a} = 1.9$  Hz,  $J_{6a,6b} = 8.5$  Hz, H-6a), 4.33 (m, 2H,  $J_{5,6b} = 4.1$  Hz, H-5, 6b), 5.14 (dd, 1H,  $J_{4,5} = 9.8$  Hz, H-4), 5.5 (dd, 1H,  $J_{3,4} = 10.0$  Hz, H-3), 6.42 (d, 1H,  $J_{1,2} = 3.8$  Hz, H-1) ppm;  $^{13}\text{C}$  n.m.r. (75 MHz):  $\delta$ , 20.5, 20.6 (x 2), 61.0, 62.3, 67.3, 71.7, 72.4, 87.4, 169.6, 169.7, 170.4 ppm; HR-FAB MS  $[\text{M}+\text{Na}]^+$  calculated for  $\text{C}_{12}\text{H}_{16}\text{BrN}_3\text{O}_7\text{Na}^+$  416.0069, found 416.0065.

### 2,3,4,6-Tetra-*O*-benzoyl- -D-glucopyranosyl trichloroacetimidate (23)



The title compound was obtained from 2,3,4,6-tetra-*O*-benzoyl-D-glucopyranose **25**<sup>1</sup> in 83% yield as a white foam as previously described.<sup>1</sup> Analytical data for **23** was in accordance with that reported previously.<sup>19</sup>

### 2,3,4,6-Tetra-*O*-benzoyl- -D-glucopyranosyl *N*-phenyltrifluoroacetimidate (24)




The title compound was obtained from 2,3,4,6-tetra-*O*-benzoyl-D-glucopyranose **25**<sup>1</sup> by adapting previously published procedure.<sup>10</sup> 2,2,2-Trifluoro-*N*-phenylethanimidoyl chloride (0.70 mL, 4.37 mmol) and  $\text{K}_2\text{CO}_3$  (0.54 g, 5.46 mmol) were added to a solution of **25** (2.17 g, 3.64 mmol) in acetone (25 mL) and the resulting mixture was stirred for 5 h at rt. The solids were filtered off through a pad of Celite and the filtrate was concentrated in *vacuo*. The residue was purified by




column chromatography on silica gel (ethyl acetate-hexanes gradient elution) to afford the title compound in 86% yield as a white foam. Analytical data for **-24**:  $R_f = 0.5$  (ethyl acetate/hexanes, 3/7, v/v);  $[\alpha]_D^{27} +49.4$  ( $c = 1.0$ ,  $\text{CHCl}_3$ );  $^1\text{H}$  n.m.r. (500 MHz):  $\delta$ , 4.51 (dd, 1H,  $J_{5,6a} = 4.4$  Hz,  $J_{6a,6b} = 12.5$  Hz, H-6a), 4.69 (m, 1H, H-5), 4.77 (dd, 1H,  $J_{5,6b} = 1.8$  Hz, H-6b), 5.67 (dd, 1H,  $J_{2,3} = 10.3$  Hz, H-2), 5.93 (dd, 1H,  $J_{4,5} = 10.1$  Hz, H-4), 6.30 (m, 3H, H-3, 2', 6'), 6.92 (d, 1H,  $J_{1,2} = 3.6$  Hz, H-1), 7.00-8.15 (m, 25H, aromatic) ppm;  $^{13}\text{C}$  n.m.r. (125 MHz):  $\delta$ , 62.4, 68.6, 70.0, 70.5, 70.8, 92.3, 119.1, 124.4, 128.6 (x 2), 128.7 (x 5), 128.8 (x 5), 128.9, 129.7, 129.9 (x 2), 130.0 (x 8), 133.3, 133.4, 133.7, 133.8, 142.8, 143.0, 165.2, 165.4, 165.7, 166.1;  $^{19}\text{F}$  n.m.r.:  $\delta$ , -65.51 (s, 3F,  $\text{CF}_3$ ) ppm; HR-FAB MS  $[\text{M}+\text{Na}]^+$  calculated for  $\text{C}_{42}\text{H}_{31}\text{F}_2\text{NO}_{10}\text{Na}^+$  790.1876, found 790.1886.

### Ethyl 2,3,4,6-tetra-*O*-benzyl-1-thio- $\beta$ -D-galactopyranoside (**52**)



The title compound was obtained as previously described.<sup>20</sup>

### Ethyl 2,3,4,6-tetra-*O*-benzyl-1-thio- $\beta$ -D-mannopyranoside (**54**)



The title compound was obtained as previously described.<sup>21</sup>

## General glycosylation procedures

**Method A.** A typical TMSOTf-promoted glycosylation procedure. A mixture of glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular sieves (4Å, 90 mg) in  $\text{CH}_2\text{Cl}_2$  (0.5 mL) or other solvent as indicated in Tables was stirred under argon for 1 h at rt. The mixture was cooled to  $-78$  °C or other temperature as indicated in Tables, TMSOTf (0.0055-0.011 mmol) was added, and the resulting mixture was stirred for 10-15 min as indicated in Tables. The solids were filtered off through a pad of Celite and rinsed successively with  $\text{CH}_2\text{Cl}_2$ . The combined filtrate (~40 mL) was washed with 1% aq. NaOH (2 x 10 mL) and water (2 x 10 mL). The organic phase was separated, dried with  $\text{MgSO}_4$ , and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford a glycoside derivative in yields listed in Tables.

**Method B.** A typical  $\text{BF}_3\text{-OEt}_2$ -promoted glycosylation procedure. A mixture of 3,3-difluoro-3*H*-indol-2-yl 2,3,4,6-tetra-*O*-benzyl- $\alpha$ -D-glucopyranoside **3** (32.7 mg, 0.047 mmol), methyl 2,3,4-tri-*O*-benzyl-  $\beta$ -D-glucopyranoside **4** (18.3 mg, 0.043 mmol), and freshly activated molecular sieves (4Å, 95 mg) in  $\text{CH}_2\text{Cl}_2$  (0.6 mL) was stirred under argon for 1 h at rt. The mixture was cooled to  $-78$  °C,  $\text{BF}_3\text{-OEt}_2$  (0.3  $\mu\text{L}$ , 0.002 mmol) was added, and the resulting mixture was stirred for 5 min. The solids were filtered off through a pad of Celite and rinsed successively with  $\text{CH}_2\text{Cl}_2$ . The combined filtrate (~40 mL) was washed with 1% aq. NaOH (2 x 10 mL) and water (2 x 10 mL). The organic phase was separated, dried with  $\text{MgSO}_4$ , and

concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford disaccharide **5** in 93% yield ( $\alpha/\beta = 1/20$ , Table 6S).

**Method C.** A typical  $\text{Cu}(\text{OTf})_2$ -promoted glycosylation procedure. A mixture of donor **3** (38.3 mg, 0.055 mmol), methyl 2,3,4-tri-*O*-benzyl- $\beta$ -D-glucopyranoside **4** (23.4 mg, 0.05 mmol), and freshly activated molecular sieves (3 Å, 110 mg) in  $\text{CH}_2\text{Cl}_2$  (0.64 mL) was stirred under argon for 1 h at rt.  $\text{Cu}(\text{OTf})_2$  (2.0 mg, 0.003 mmol) was added and the resulting mixture was stirred for 5 min. The solids were filtered off through a pad of Celite and rinsed successively with  $\text{CH}_2\text{Cl}_2$ . The combined filtrate (~40 mL) was washed with 1% aq. NaOH (2 x 10 mL) and water (2 x 10 mL). The organic phase was separated, dried with  $\text{MgSO}_4$ , and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford disaccharide **5** in 97% yield ( $\alpha/\beta$  only, Table 6S).

**Method D.** A typical  $\text{MeOTf}$ -promoted glycosylation procedure. A mixture of donor **3** (30.6 mg, 0.044 mmol), acceptor **4** (18.7 mg, 0.040 mmol), and freshly activated molecular sieves (4Å, 90 mg) in  $\text{CH}_2\text{Cl}_2$  (0.5 mL) was stirred under argon for 1 h at rt.  $\text{MeOTf}$  (0.55  $\mu\text{L}$ , 0.0044 mmol) was added and the resulting mixture was stirred for 10 min. The solids were filtered off through a pad of Celite and rinsed successively with  $\text{CH}_2\text{Cl}_2$ . The combined filtrate (~40 mL) was washed with 1% aq. NaOH (2 x 10 mL) and water (2 x 10 mL). The organic phase was separated, dried with  $\text{MgSO}_4$ , and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford disaccharide **5** in 91% yield ( $\alpha/\beta = 1/>25$ , Table 6S)

**Method E.** A typical  $\text{AgOTf}$ -promoted glycosylation procedure. A mixture of donor **3** (43.5 mg, 0.062 mmol), acceptor **4** (26.7 mg, 0.057 mmol), and freshly activated molecular sieves (4Å, 120 mg) in  $\text{CH}_2\text{Cl}_2$  (0.73 mL) was stirred under argon for 1 h at rt.  $\text{AgOTf}$  (7.3 mg, 0.028 mmol) was added and the resulting mixture was stirred for 24 h. The solids were filtered off through a pad of Celite and rinsed successively with  $\text{CH}_2\text{Cl}_2$ . The combined filtrate (~40 mL) was washed with 1% aq. NaOH (2 x 10 mL) and water (2 x 10 mL). The organic phase was separated, dried with  $\text{MgSO}_4$ , and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford disaccharide **5** in 71% yield ( $\alpha/\beta = 1/1.6$ , Table 6S).

**Method F.** A typical  $\text{PdCl}_2$ -promoted glycosylation procedure. A mixture of donor **3** (33.2 mg, 0.048 mmol), acceptor **4** (20.3 mg, 0.044 mmol), and freshly activated molecular sieves (4Å, 90 mg) in  $\text{CH}_2\text{Cl}_2$  (0.55 mL) was stirred under argon for 1 h at rt.  $\text{PdCl}_2$  (2.55 mg, 0.014 mmol) was added and the resulting mixture was stirred for 36 h. The solids were filtered off through a pad of Celite and rinsed successively with  $\text{CH}_2\text{Cl}_2$ . The combined filtrate (~40 mL) was washed with 1% aq. NaOH (2 x 10 mL) and water (2 x 10 mL). The organic phase was separated, dried with  $\text{MgSO}_4$ , and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford disaccharide **5** in 57% yield ( $\alpha/\beta = 1/1.7$ , Table 6S).


**Method G.** A typical  $\text{TMSClO}_4$ -promoted glycosylation procedure. A mixture of donor **3** (0.044 mmol), acceptor **4** (0.040 mmol), and freshly activated molecular sieves (3 Å, 90 mg) in  $\text{Et}_2\text{O}$  (0.5 mL) or  $\text{Et}_2\text{O}/1.4$ -dioxane (0.5 mL, 1/1, v/v) was stirred under argon for 1 h at rt.  $\text{TMSClO}_4$ <sup>22</sup>

(0.0044 mmol) was added and the resulting mixture was stirred for 5 min. The solids were filtered off through a pad of Celite and rinsed successively with CH<sub>2</sub>Cl<sub>2</sub>. The combined filtrate (~40 mL) was washed with 1% aq. NaOH (2 x 10 mL) and water (2 x 10 mL). The organic phase was separated, dried with MgSO<sub>4</sub>, and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford disaccharide **5** in 75% ( $\alpha/\beta = 5/1$ , Table 6S) or 54% yield ( $\alpha/\beta = 6.2/1$ ), respectively.

**Method H.** A typical *Bi(OTf)<sub>3</sub>*-promoted glycosylation procedure. A mixture of donor **3** (41.3 mg, 0.059 mmol), acceptor **4** (25.2 mg, 0.054 mmol), and freshly activated molecular sieves (4Å, 120 mg) in CH<sub>2</sub>Cl<sub>2</sub> (0.7 mL) was stirred under argon for 1 h at rt. The reaction was cooled to -60 °C followed by the addition of *Bi(OTf)<sub>3</sub>* (3.9 mg, 0.006 mmol) and the resulting mixture was stirred for 20 min. The solids were filtered off through a pad of Celite and rinsed successively with CH<sub>2</sub>Cl<sub>2</sub>. The combined filtrate (~40 mL) was washed with 1% aq. NaOH (2 x 10 mL) and water (2 x 10 mL). The organic phase was separated, dried with MgSO<sub>4</sub>, and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford disaccharide **5** in 85% yield, ( $\alpha/\beta = 1/7.0$ , Table 6S).


**Method I.** A typical *SnCl<sub>4</sub>*-promoted glycosylation procedure. A mixture of 3,3-difluoro-3*H*-indol-2-yl 2,3,4,6-tetra-*O*-acetyl- $\alpha$ -D-glucopyranoside **14** (25.8 mg, 0.051 mmol), acceptor **4** (21.8 mg, 0.046 mmol), and freshly activated molecular sieves (4Å, 90 mg) in CH<sub>2</sub>Cl<sub>2</sub> (0.5 mL) was stirred under argon for 1 h at rt. SnCl<sub>4</sub> (0.6  $\mu$ L, 0.005 mmol) was added and the resulting mixture was stirred for 10 min (Table 4). The solids were filtered off through a pad of Celite and rinsed successively with CH<sub>2</sub>Cl<sub>2</sub>. The combined filtrate (~40 mL) was washed with 1% aq. NaOH (2 x 10 mL) and water (2 x 10 mL). The organic phase was separated, dried with MgSO<sub>4</sub>, and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford disaccharide **41** in 80% yield (Table 9S).

### 2-Propyl 2,3,4,6-tetra-*O*-benzyl- $\alpha$ -D-glucopyranoside (**27**)




The title compound was obtained by Method A from donor **3** and isopropanol **26** as a white amorphous solid in 77% yield (only). Analytical data for **27** was in accordance with that reported previously.<sup>23</sup>

### Methyl 2,3,4-tri-*O*-benzyl-6-*O*-(2,3,4,6-tetra-*O*-benzyl- $\alpha$ -D-glucopyranosyl)- $\alpha$ -D-glucopyranoside (**5**)




The title compound was obtained by Methods A-H from donor **3** and acceptor **4**<sup>24</sup> in 54-97% yield ( / ranging from 6.2/1 to -only, see Tables). Analytical data for **5** was in accordance with that reported previously.<sup>25,26</sup>

**Methyl 2,3,4-tri-*O*-benzoyl-6-*O*-(2,3,4,6-tetra-*O*-benzyl-*D*-glucopyranosyl)-*D*-glucopyranoside (29)**




The title compound was obtained by Method A from donor **3** and methyl 2,3,4-tri-*O*-benzoyl-*D*-glucopyranoside **28**<sup>27</sup> in CH<sub>2</sub>Cl<sub>2</sub> or EtCN in 89% ( / = 1/11) or 87% yield ( / = 1/18), respectively. Analytical data for **29** was in accordance with that reported previously.<sup>28</sup>

**6-*O*-(2,3,4,6-Tetra-*O*-benzyl-*D*-glucopyranosyl)-1,2:3,4-di-*O*-isopropylidene-*D*-galactopyranose (31)**




The title compound was obtained by Method A from donor **3** and 1,2:3,4-di-*O*-isopropylidene-*D*-galactopyranose **30** in CH<sub>2</sub>Cl<sub>2</sub> or EtCN in 85% ( / = 1/12) or 89% yield ( only), respectively. Analytical data for **31** was in accordance with that reported previously.<sup>29</sup>

**Methyl 2,3,6-tri-*O*-benzyl-4-*O*-(2,3,4,6-tetra-*O*-benzyl-*D*-glucopyranosyl)-*D*-glucopyranoside (33)**




The title compound was obtained by Method A from donor **3** and methyl 2,3,6-tri-*O*-benzyl-*D*-glucopyranoside **32**<sup>24</sup> in CH<sub>2</sub>Cl<sub>2</sub> or EtCN in 94% ( / = 1/4) or 92% yield ( / = 1/12), respectively. Analytical data for **33** was in accordance with that reported previously.<sup>28</sup>

**Methyl 2-*O*-(2,3,4,6-tetra-*O*-benzyl-*D*-glucopyranosyl)-3,4,6-tri-*O*-benzyl-*D*-glucopyranoside (35)**




The title compound was obtained by Method A from donor **3** and methyl 3,4,6-tri-*O*-benzyl-*D*-glucopyranoside **34**<sup>24</sup> in CH<sub>2</sub>Cl<sub>2</sub> or EtCN in 90% ( / = 1/6.0) or 88% yield ( / = 1/15), respectively. Analytical data for **35** was in accordance with that reported previously.<sup>30</sup>

**(3 $\beta$ )-Cholest-5-en-3-yl 2,3,4,6-tetra-*O*-benzyl-*D*-glucopyranoside (37)**




The title compound was obtained by Method A from donor **3** and (3 $\beta$ )-cholest-5-en-3-ol **36** as a white amorphous solid in 86% yield ( -only). Analytical data for **37** was in accordance with that reported previously.<sup>31</sup>

### 1-Adamantyl 2,3,4,6-tetra-*O*-benzyl-D-glucopyranoside (**39**)




The title compound was obtained by Method A from donor **3** and 1-adamantol **38** as a white amorphous solid in 88% yield ( / = 1/23). Analytical data for **39** was in accordance with that reported previously.<sup>31</sup>

### Methyl 2-*O*-(3,4,6-tri-*O*-acetyl-2-*O*-benzyl- -D-glucopyranosyl)-3,4,6-tri-*O*-benzyl- -D-glucopyranoside (**40**)




The title compound was obtained by Method A from donor  $\alpha$ -**12** or donor -**12** and acceptor **34**<sup>24</sup> as a clear film in 89% or 88% yield ( $\alpha$  only), respectively. Analytical data for **40** was in accordance with that reported previously.<sup>30</sup>

### Methyl 6-*O*-(2,3,4,6-tetra-*O*-benzoyl- -D-glucopyranosyl)-2,3,4-tri-*O*-benzyl- -D-glucopyranoside (**41**)




The title compound was obtained by Method I from donor **14** and acceptor **4**<sup>24</sup> as a clear film in 80% yield. Analytical data for **41** were essentially the same as reported previously.<sup>32</sup>

### Methyl 6-*O*-(2,3,4,6-tetra-*O*-benzoyl- -D-glucopyranosyl)-2,3,4-tri-*O*-benzyl- -D-glucopyranoside (**42**)




The title compound was obtained by Method A from donor **16** and acceptor **4**<sup>24</sup> as a clear film in 94% yield. Analytical data for **42** were essentially the same as reported previously.<sup>24</sup>

### 6-*O*-(2,3,4,6-Tetra-*O*-benzoyl- -D-glucopyranosyl)-1,2:3,4-di-*O*-isopropylidene- -D-galactopyranose (**43**)




The title compound was obtained by Method A from donor **16** and acceptor **30** in 86% yield. Analytical data for **43** were essentially similar as reported previously.<sup>30</sup>

**Methyl 4-*O*-(2,3,4,6-tetra-*O*-benzoyl- -D-glucopyranosyl)-2,3,6-tri-*O*-benzyl- -D-glucopyranoside (44)**




The title compound was obtained by Method A from donor **16** and acceptor **32**<sup>24</sup> as a clear film in 90% yield. Analytical data for **44** were essentially the same as reported previously.<sup>24</sup>

**Methyl 2-*O*-(2,3,4,6-tetra-*O*-benzoyl- -D-glucopyranosyl)-3,4,6-tri-*O*-benzyl- -D-glucopyranoside (45)**




The title compound was obtained by Method A from donor **16** and acceptor **34**<sup>24</sup> as a clear film in 93% yield. Analytical data for **45** were essentially the same as reported previously.<sup>24</sup>

**Methyl 6-*O*-(2,3,4,6-tetra-*O*-benzoyl- -D-galactopyranosyl)-2,3,4-tri-*O*-benzyl- -D-glucopyranoside (46)**




The title compound was obtained by Method A from donor **18** and acceptor **4**<sup>24</sup> as a clear film in 98% yield. Analytical data for **46** were essentially the same as reported previously.<sup>33</sup>

**Methyl 4-*O*-(2,3,4,6-tetra-*O*-benzoyl- -D-galactopyranosyl)-2,3,6-tri-*O*-benzyl- -D-glucopyranoside (47)**




The title compound was obtained by Method A from donor **18** and acceptor **32**<sup>24</sup> as a clear film in 98% yield. Analytical data for **47** were essentially the same as reported previously.<sup>30</sup>

**Methyl 6-*O*-(2,3,4,6-tetra-*O*-benzoyl- -D-mannopyranosyl)-2,3,4-tri-*O*-benzyl- -D-glucopyranoside (48)**



The title compound was obtained by Method A from donor **20** and acceptor **4**<sup>24</sup> as a clear film in 93% yield. Analytical data for **48** were essentially the same as reported previously.<sup>30</sup>

**Methyl 4-O-(2,3,4,6-tetra-O-benzoyl- -D-mannopyranosyl)-2,3,6-tri-O-benzyl- -D-glucopyranoside (49)**




The title compound was obtained by Method A from donor **20** and acceptor **32**<sup>24</sup> as a clear film in 90% yield. Analytical data for **49** were essentially the same as reported previously.<sup>34</sup>

**A typical procedure for regenerative glycosylation**


A mixture of ethyl 2,3,4,6-tetra-*O*-benzyl-1-thio- -D-glucopyranoside **6**<sup>11</sup> (30 mg, 0.051 mmol) and activated molecular sieves (3 Å, 90 mg) in CH<sub>2</sub>Cl<sub>2</sub> (0.5 mL) was stirred under argon for 1 h at rt. The mixture was cooled to 0 °C, bromine (0.27 μL, 0.01 mmol) was added, and the resulting mixture was kept for 15 min at 0 °C. After that, 3,3-difluorooxindole (0.9 mg - 8.9 mg, 0.0051-0.051 mmol, see Table 2 of the manuscript), and Ag<sub>2</sub>O (36 mg, 0.16 mmol) were added to the reaction mixture and the resulting mixture was stirred for 10 min - 1 h at 0 °C. Methyl 2,3,4-tri-*O*-benzyl- -D-glucopyranoside **4** (18.3 mg, 0.039 mmol) and BF<sub>3</sub>-OEt<sub>2</sub> (0.33 μL, 0.0025 mmol) were added and the reaction was stirred for 10 min - 5 h (see Table 2 of the manuscript). The solids were filtered off through a pad of Celite and rinsed successively with CH<sub>2</sub>Cl<sub>2</sub>. The combined filtrate (~20 mL) was washed with 1% aq. NaOH (2 x 10 mL) and water (2 x 10 mL). The organic phase was separated, dried with MgSO<sub>4</sub>, and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (ethyl acetate-hexanes gradient elution) to afford disaccharide **5** in 9-90% yield (see Table 2 of the manuscript).

**Methyl 3-O-(2,3,4,6-tetra-O-benzoyl- -D-glucopyranosyl)-2,4,6-tri-O-benzyl- -D-glucopyranoside (51)**




The title compound was obtained from donor **6** and acceptor **50**<sup>24</sup> as a white amorphous solid in 62% yield ( / = 1/1.0). The analytical data for **7** was essentially the same as reported previously.<sup>24</sup>

**Methyl 2,3,4-tri-O-benzyl-6-O-(2,3,4,6-tetra-O-benzyl-D-galactopyranosyl)- -D-glucopyranoside (53)**



The title compound was obtained from glycosyl donor **52** and acceptor **4**<sup>24</sup> as a white amorphous solid in 69% yield ( / = 1/1.1). Analytical data for **53** was in accordance with that reported previously.<sup>26,35</sup>

**Methyl 2,3,4-tri-*O*-benzyl-6-*O*-(2,3,4,6-tetra-*O*-benzyl-D-mannopyranosyl)- $\beta$ -D-glucopyranoside (55)**








The title compound was obtained from donor **54** and acceptor **4** as a white amorphous solid in 75% yield ( $\alpha/\beta = 2.5/1$ ). The title compound was reported previously.<sup>36</sup>





NMR spectra

**2,3,4,6-Tetra-*O*-benzyl- / -D-glucopyranosyl trichloroacetimidate (1)**








2,3,4,6-Tetra-*O*-benzyl- / -*D*-glucopyranosyl *N*-phenyltrifluoroacetimidate (2)






(<sup>1</sup>H NMR 500 MHz, CDCl<sub>3</sub>)







(2D NMR 500 MHz, CDCl<sub>3</sub>)



**3,3-Difluoro-3*H*-indol-2-yl 2,3,4,6-tetra-*O*-benzyl- $\alpha$ -D-glucopyranoside (3)**






(2D NMR 300 MHz, CDCl<sub>3</sub>)



**Methyl 6-O-(2,3,4,6-tetra-O-benzyl- / -D-glucopyranosyl)-2,3,4-tri-O-benzyl- -D-glucopyranoside (5)**



**(<sup>1</sup>H NMR 300 MHz, CDCl<sub>3</sub>)**





**(<sup>13</sup>C NMR 150 MHz, CDCl<sub>3</sub>)**




(2D NMR 300 MHz, CDCl<sub>3</sub>)





**3,3-Difluoro-3*H*-indol-2-yl 2,3,4,6-tetra-*O*-benzyl- -*D*-mannopyranoside (10)**



**(<sup>1</sup>H NMR 300 MHz, CDCl<sub>3</sub>)**





**(<sup>13</sup>C NMR 75 MHz, CDCl<sub>3</sub>)**






(2D NMR 300 MHz, CDCl<sub>3</sub>)









(2D NMR 300 MHz, CDCl<sub>3</sub>)

**3,3-Difluoro-3*H*-indol-2-yl 3,4,6-tri-*O*-acetyl-2-*O*-benzyl- -*D*-glucopyranoside ( -12)**












(2D NMR 300 MHz, CDCl<sub>3</sub>)





**3,3-Difluoro-3*H*-indol-2-yl 2,3,4,6-tetra-*O*-acetyl-  $\beta$ -D-glucopyranoside (14)**



( $^1\text{H}$  NMR 300 MHz,  $\text{CDCl}_3$ )





( $^{13}\text{C}$  NMR 75 MHz,  $\text{CDCl}_3$ )




(2D NMR 300 MHz, CDCl<sub>3</sub>)



**2,3,4,6-Tetra-*O*-benzoyl- -D-galactopyranosyl bromide (15)**



(<sup>1</sup>H NMR 300 MHz, CDCl<sub>3</sub>)





(<sup>13</sup>C NMR 75 MHz, CDCl<sub>3</sub>)





(2D NMR 300 MHz, CDCl<sub>3</sub>)






(2D NMR 300 MHz, CDCl<sub>3</sub>)



**3,3-Difluoro-3*H*-indol-2-yl 2,3,4,6-tetra-*O*-benzoyl-*D*-galactopyranoside (18)**



( $^1\text{H NMR}$  300 MHz,  $\text{CDCl}_3$ )





( $^{13}\text{C NMR}$  75 MHz,  $\text{CDCl}_3$ )




(2D NMR 300 MHz, CDCl<sub>3</sub>)





**3,3-Difluoro-3*H*-indol-2-yl 2,3,4,6-tetra-*O*-benzoyl-*-D*-mannopyranoside (20)**



(<sup>1</sup>H NMR 300 MHz, CDCl<sub>3</sub>)





(<sup>13</sup>C NMR 75 MHz, CDCl<sub>3</sub>)




(2D NMR 300 MHz, CDCl<sub>3</sub>)



3,4,6-Tri-*O*-acetyl-2-azido-2-deoxy- -D-glucopyranosyl bromide (21)



(<sup>1</sup>H NMR 300 MHz, CDCl<sub>3</sub>)





(<sup>13</sup>C NMR 75 MHz, CDCl<sub>3</sub>)





(2D NMR 300 MHz, CDCl<sub>3</sub>)






(2D NMR 300 MHz, CDCl<sub>3</sub>)



**2,3,4,6-Tetra-*O*-benzoyl- $\beta$ -D-glucopyranosyl N-phenyltrifluoroacetimidate (24)**



**( $^1\text{H}$  NMR 500 MHz,  $\text{CDCl}_3$ )**





**( $^{13}\text{C}$  NMR 125 MHz,  $\text{CDCl}_3$ )**




(2D NMR 500 MHz, CDCl<sub>3</sub>)





**Isopropyl 2,3,4,6-tetra-*O*-benzyl- $\alpha$ -D-glucopyranoside (27)**



( $^1\text{H NMR}$  300 MHz,  $\text{CDCl}_3$ )





( $^{13}\text{C NMR}$  75 MHz,  $\text{CDCl}_3$ )




(2D NMR 300 MHz, CDCl<sub>3</sub>)



**Methyl 6-O-(2,3,4,6-tetra-O-benzyl- $\alpha$ -D-glucopyranosyl)-2,3,4-tri-O-benzoyl- $\beta$ -D-glucopyranoside (29)**



( $^1\text{H NMR}$  300 MHz,  $\text{CDCl}_3$ )




( $^{13}\text{C NMR}$  75 MHz,  $\text{CDCl}_3$ )




(2D NMR 300 MHz, CDCl<sub>3</sub>)


**6-O-(2,3,4,6-Tetra-O-benzyl- $\alpha$ -D-glucopyranosyl)-1,2:3,4-di-O-isopropylidene-D-galactopyranose (31)**



**31**





$(^1\text{H NMR 300 MHz, CDCl}_3)$



$(^{13}\text{C NMR 150 MHz, CDCl}_3)$










(2D NMR 300 MHz, CDCl<sub>3</sub>)



Methyl 2-*O*-(2,3,4,6-tetra-*O*-benzyl- / -*D*-glucopyranosyl)-3,4,6-tri-*O*-benzyl- -*D*-glucopyranoside (35)






(<sup>1</sup>H NMR 300 MHz, CDCl<sub>3</sub>)





(<sup>13</sup>C NMR 150 MHz, CDCl<sub>3</sub>)






(3 $\beta$ )-Cholest-5-en-3-yl 2,3,4,6-tetra-*O*-benzyl- $\beta$ -D-glucopyranoside (37)







(2D NMR 300 MHz, CDCl<sub>3</sub>)



1-Adamantyl 2,3,4,6-tetra-*O*-benzyl- $\alpha$ -D-glucopyranoside (39)





(2D NMR 300 MHz, CDCl<sub>3</sub>)







## References

- (1) Egusa, K.; Kusumoto, S.; Fukase, K. *Eur. J. Org. Chem.* **2003**, 2003, 3435-3445.
- (2) Torres, J. C.; Garden, S. J.; Pinto, A. C. *Tetrahedron* **1999**, 55, 1881-1892.
- (3) Dinkelaar, J.; Witte, M. D.; van den Bos, L. J.; Overkleef, H. S.; van der Marel, G. A. *Carbohydr. Res.* **2006**, 341, 1723-1729.
- (4) Kim, I. S.; Kim, S. J.; Lee, J. K.; Li, Q. R.; Jung, Y. H. *Carbohydr. Res.* **2007**, 342, 1502-1509.
- (5) Lemieux, R. U. In *Methods in Carbohydrate Chemistry*; Whistler, R. L., Wolfrom, M. L., Eds.; Academic Press Inc.: New York and London, 1963; Vol. 2, p 221-222.
- (6) Lemieux, R. U. In *Methods in Carbohydrate Chemistry*; Whistler, R. L., Wolfrom, M. L., Eds.; Academic Press Inc.: New York and London, 1963; Vol. 2, p 226-228.
- (7) Kartha, K. P. R.; Jennings, H. J. *J. Carbohydr. Chem.* **1990**, 9, 777-781.
- (8) Dowlut, M.; Hall, D. G.; Hindsgaul, O. *J. Org. Chem.* **2005**, 70, 9809-9813.
- (9) Schmidt, R., R.; Stumpp, M. *Liebigs Ann. Chem.* **1983**, 1249-1256.
- (10) Yu, B.; Tao, H. *Tetrahedron Lett.* **2001**, 42, 2405-2407.
- (11) Andersson, F.; Fugedi, P.; Garegg, P. J.; Nashed, M. *Tetrahedron Lett.* **1986**, 27, 3919-3922.
- (12) Excoffier, G.; Gagnaire, D. Y.; Vignon, M. R. *Carbohydr. Res.* **1976**, 46, 215-226.
- (13) Brennan, S.; Finan, P. A. *J. Chem. Soc., C* **1970**, 1742-1744.
- (14) Parameswar, A. R.; Hawkins, J. A.; Mydock, L. K.; Sands, M. S.; Demchenko, A. V. *Eur. J. Org. Chem.* **2010**, 3269-3274.
- (15) Pavliak, V.; Kovac, P. *Carbohydr. Res.* **1991**, 210, 333-337.
- (16) Suárez, J. R.; Trastoy, B.; Pérez-Ojeda, M. E.; Marín-Barrios, R.; Chiara, J. L. *Adv. Synth. Catal.* **2010**, 352, 2515-2520.
- (17) Paulsen, H.; Wulff, A.; Heitman, A. C. *Liebigs Ann. Chem.* **1988**, 1073-1078.
- (18) Rowan, A. S.; Nicely, N. I.; Cochrane, N.; Wlassoff, W. A.; Claiborne, A.; Hamilton, C. *J. Organic & biomolecular chemistry* **2009**, 7, 4029-4036.
- (19) Nigudkar, S. S.; Parameswar, A. R.; Pornsuriyasak, P.; Stine, K. J.; Demchenko, A. V. *Org. Biomol. Chem.* **2013**, 11, 4068-4076.
- (20) Weïwer, M.; Sherwood, T.; Linhardt, R. J. *J. Carbohydr. Chem.* **2008**, 27, 420-427.
- (21) Wang, C.; Sanders, B.; Baker, D. C. *Can. J. Chem.* **2011**, 89, 959-963.
- (22) Wakao, M.; Nakai, Y.; Fukase, K.; Kusumoto, S. *Chem. Lett.* **1999**, 27-28.
- (23) Jansson, K.; Noori, G.; Magnusson, G. *J. Org. Chem.* **1990**, 55, 3181-3185.
- (24) Ranade, S. C.; Kaeothip, S.; Demchenko, A. V. *Org. Lett.* **2010**, 12, 5628-5631.
- (25) Garcia, B. A.; Gin, D. Y. *J. Am. Chem. Soc.* **2000**, 122, 4269-4279.
- (26) Nguyen, H. M.; Chen, Y. N.; Duron, S. G.; Gin, D. Y. *J. Am. Chem. Soc.* **2001**, 123, 8766-8772.
- (27) Zhang, F.; Zhang, W.; Zhang, Y.; Curran, D. P.; Liu, G. *J. Org. Chem.* **2009**, 74, 2594-2597.
- (28) Boltje, T. J.; Kim, J.-H.; Park, J.; Boons, G.-J. *Org. Lett.* **2011**, 13, 284-287.
- (29) Koshiba, M.; Suzuki, N.; Arihara, R.; Tsuda, T.; Nambu, H.; Nakamura, S.; Hashimoto, S. *Chem. Asian J.* **2008**, 3, 1664-1677.
- (30) Pornsuriyasak, P.; Demchenko, A. V. *Chem. Eur. J.* **2006**, 12, 6630-6646.
- (31) Mensah, E. A.; Azzarelli, J. M.; Nguyen, H. M. *J. Org. Chem.* **2009**, 74, 1650-1657.
- (32) Huang, K. T.; Winssinger, N. *Eur. J. Org. Chem.* **2007**, 1887-1890.

- (33) Tatai, J.; Fugedi, P. *Org. Lett.* **2007**, *9*, 4647-4650.
- (34) Kim, K. S.; Fulse, D. B.; Baek, J. Y.; Lee, B. Y.; Jeon, H. B. *J. Am. Chem. Soc.* **2008**, *130*, 8537-8547.
- (35) Vankar, Y. D.; Vankar, P. S.; Behrendt, M.; Schmidt, R. R. *Tetrahedron* **1991**, *47*, 9985-9992.
- (36) Hotha, S.; Kashyap, S. *J. Am. Chem. Soc.* **2006**, *128*, 9620-9621.